Tag Archives: mRCC

December, 2017

11 December
Genentech’s Tecentriq and Avastin Reduced Risk of Disease Worsening or Death in Late-Stage Kidney Cancer Trial

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) and Avastin®(bevacizumab) provided a statistically significant and clinically meaningful reduction …
Share

22 February
Committee Recommends that Argos Therapeutics Discontinue Late-Stage Kidney Cancer Trial for Futility

DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the Independent Data Monitoring Committee (IDMC) for the company’s pivotal Phase 3 ADAPT clinical trial …
Share

13 June
IDMC Recommends Continuation of Argos Therapeutics Late-Stage RCC Study

DURHAM, N.C., June 13, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that the independent data monitoring committee (IDMC) for the Company’s pivotal Phase …
Share